Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: Lack of mutations in the BRAF and EGFR genes

Virchows Archiv

Volumn 448, Issue 6, 2006, Pages 788-796

  Immervoll, Heike ^a,b   Hoem, Dag ^b   Kugarajh, Kalaiarasy ^a   Steine, Solrun J ^a   Molven, Anders ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

BRAF; EGFR; KRAS; Mutation analysis; Pancreatic cancer

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; RAF PROTEIN; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GENETICS; CANCER SURVIVAL; CODON; CONTROLLED STUDY; DNA EXTRACTION; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LASER MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; TISSUE SECTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; DNA, NEOPLASM; FEMALE; GENES, ERBB-1; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; SURVIVAL RATE;

EID: 33744725273     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-006-0191-8     Document Type: Article

References (49)

1. Akslen LA, Angelini S, Straume O, Bachmann IM, Molven A, Hemminki K, Kumar R (2005) BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 125:312-317
2. American Joint Committee on Cancer (1998) Cancer staging handbook, 5th edn. Lippincott Raven, Philadelphia
3. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N et al (2001) Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85:692-696
4. Banerjee SK, Makdisi WF, Weston AP, Campbell DR (1997) A two-step enriched-nested PCR technique enhances sensitivity for detection of codon 12 K-ras mutations in pancreatic adenocarcinoma. Pancreas 15:16-24
5. Bartsch DK (2003) Familial pancreatic cancer. Br J Surg 90:386-387
6. Blaker H, Helmchen B, Bonisch A, Aulmann S, Penzel R, Otto HF, Rieker RJ (2004) Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas. Scand J Gastroenterol 39:748-753
7. Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, Hempen PM, Hilgers W, Yeo CJ, Hruban RH et al (2003) BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol 163:1255-1260
8. Cancer Registry of Norway (2005) Cancer in Norway 2002. Cancer Registry of Norway, Oslo
9. Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, Haglund C (2005) Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study reevaluating the data of the Finnish Cancer Registry. Gut 54:385-387
10. Chan TL, Zhao W, Leung SY, Yuen ST (2003) BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 63:4878-4881
11. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954
12. Domingo E, Espin E, Armengol M, Oliveira C, Pinto M, Duval A, Brennetot C, Seruca R, Hamelin R, Yamamoto H et al (2004) Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer 39:138-142
13. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K, Takenoshita S (2003) BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22:6455-6457
14. Goggins M, Offerhaus GJ, Hilgers W, Griffin CA, Shekher M, Tang D, Sohn TA, Yeo CJ, Kern SE, Hruban RH (1998) Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol 152:1501-1507
15. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL (1993) K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143:545-554
16. Hruban RH, Goggins M, Parsons J, Kern SE (2000) Progression model for pancreatic cancer. Clin Cancer Res 6:2969-2972
17. International Agency for Research on Cancer (2000) Tumours of the digestive system. In: Hamilton SR, Aaltonen LA (eds) WHO classification of tumours. IARC Press, Lyon
18. Ishimura N, Yamasawa K, Karim Rumi MA, Kadowaki Y, Ishihara S, Amano Y, Nio Y, Higami T, Kinoshita Y (2003) BRAF and K-ras gene mutations in human pancreatic cancers. Cancer Lett 199:169-173
19. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics, 2003. CA Cancer J Clin 53:5-26
20. Kawesha A, Ghaneh P, Andren-Sandberg A, Ograeid D, Skar R, Dawiskiba S, Evans JD, Campbell F, Lemoine N, Neoptolemos JP (2000) K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16 (INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 89:469-474
21. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG (1992) Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 90:1352-1360
22. Lee EJ, Choi C, Park CK, Maeng L, Lee JQ, Lee A, Kim K-M (2005) Tracing origin of serrated adenomas with BRAF and KRAS mutations. Virchows Arch 447:597-602
23. Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363:1049-1057
24. Lohr M, Kloppel G, Maisonneuve P, Lowenfels AB, Luttges J (2005) Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 7:17-23
25. Loukopoulos P, Kanetaka K, Takamura M, Shibata T, Sakamoto M, Hirohashi S (2004) Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 29:193-203
26. Lowenfels AB, Maisonneuve P (2004) Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 34:238-244
27. Luttges J, Schlehe B, Menke MA, Vogel I, Henne-Bruns D, Kloppel G (1999) The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer 85:1703-1710
28. Lynch HT, Shaw TG, Lynch JF (2004) Inherited predisposition to cancer: a historical overview. Am J Med Genet C Semin Med Genet 129:5-22
29. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
30. Maple JT, Smyrk TC, Boardman LA, Johnson RA, Thibodeau SN, Chari ST (2005) Defective DNA mismatch repair in long-term (> or =3 years) survivors with pancreatic cancer. Pancreatology 5:220-227
31. Miller CJ, Cheung M, Sharma A, Clarke L, Helm K, Mauger D, Robertson GP (2004) Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol 123:990-992
32. Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Kimura K, Kambara T, MacPhee DG, Young J, Leggett BA et al (2004) Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 22:4584-4594
33. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS (2005) Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 7:413-421
34. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500
35. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2002) Tumorigenesis: RAF/ RAS oncogenes and mismatch-repair status. Nature 418:934
36. Ren YX, Xu GM, Li ZS, Song YG (2004) Detection of point mutation in K-ras oncogene at codon 12 in pancreatic diseases. World J Gastroenterol 10:881-884
37. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M (2003) Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 27:324-329
38. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ et al (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 57:1731-1734
39. Saetta AA, Papanastasiou P, Michalopoulos NV, Gigelou F, Korkolopoulou P, Bei T, Patsouris E (2004) Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. Virchows Arch 445:179-182
40. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554
41. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W et al (1997) Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57:3126-3130
42. Sessa F, Bonato M, Bisoni D, Ranzani GN, Capella C (1998) Ki-ras and p53 gene mutations in pancreatic ductal carcinoma: a relationship with tumor phenotype and survival. Eur J Histochem 42(Spec Issue):67-76
43. Sommerer F, Vieth M, Markwarth A, Rohrich K, Vomschloss S, May A, Ell C, Stolte M, Hengge UR, Wittekind C et al (2004) Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene 23:554-558
44. Song MM, Nio Y, Dong M, Tamura K, Furuse K, Tian YL, He SG, Shen K (2000) Comparison of K-ras point mutations at codon 12 and p21 expression in pancreatic cancer between Japanese and Chinese patients. J Surg Oncol 75:176-185
45. van Heek NT, Meeker AK, Kern SE, Yeo CJ, Lillemoe KD, Cameron JL, Offerhaus GJ, Hicks JL, Wilentz RE, Goggins MG et al (2002) Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 161:1541-1547
46. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW (2004) Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91:586-594
47. Weir B, Zhao X, Meyerson M (2004) Somatic alterations in the human cancer genome. Cancer Cell 6:433-438
48. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109
49. Yamamoto H, Itoh F, Nakamura H, Fukushima H, Sasaki S, Perucho M, Imai K (2001) Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res 61:3139-3144